Textbook of Personalized Medicine - Second Edition [2015]

721

J
Jackson Laboratory for Genomic Medicine , 619
Janus 2 tyrosine kinase (JAK2) gene , 326, 327
Johns Hopkins Kimmel Cancer Center , 620

K
KALYDECO™ , 548
Kidney transplantation , 558–559

L
LabCD , 58
LabChip , 57
Laboratory Multiple Analyte Profi le (LabMap)
technology , 65
Lactose intolerance , 568
L-asparaginase (L-ASP) , 220–221
Lausanne Institutional Biobank , 634
Life science industry
BioIT Alliance , 597–598
clinical laboratories, role of , 598
molecular imaging, role of
CNS drug development , 601–602
commercial development of , 602–603
oncology, drug development in ,
599–601
PET , 598–599
Ligase detection reaction (LDR) , 48
Linkage disequilibrium (LD) methods , 60
Liver cancer management , 345–346
Loci Analysis for Rearrangement Link
(LARaLink 2.0) , 636
Locked nucleic acids (LNA) , 66
Long interspersed nucleotide element-1
(LINE-1) , 341
Loss of heterozygosity (LOH) , 206, 271
Low bone density (LBD) , 581
Low-grade gliomas (LGG) , 287–288
Lung adenocarcinoma (LAD) , 237, 351, 352
Lung cancer management
ceritinib , 347
chemotherapy , 354
classifi cation system , 353
crizotinib , 347
EGFR tyrosine kinase inhibitor treatment ,
347–351
KIF5B/RET fusion oncogene , 352
metabolic biomarkers , 352–353
microRNAs , 353
molecular subtyping , 351
platinum-based therapy , 352
prognosis of , 355

respiratory papillomatosis , 354

Lung Subtype Platform (LSP™) , 351

Lupus Therasight™ , 554

Lymphomas

Adcetris™ , 336

B cell lymphomas , 334–335

follicular lymphoma , 336

Lysosomal storage disorders (LSDs) , 537–538

M

Magnetic resonance imaging (MRI) , 81, 578, 598

Major histocompatibility complex (MHC) ,

142, 244, 551, 552

Malaria , 406–407

Malarone , 406

Malignant melanoma , 355–356

BRAF mutation, inhibitors of , 356–357

drug resistance , 357

heat shock protein , 357

Mammalian target of rapamycin (mTOR) , 280

MammaPrint test , 309

Mannose 6-phosphate/insulin-like growth

factor 2 receptor (M6P/IGF2R) , 264

Maraviroc Once daily with Darunavir

Enhanced by Ritonavir in a Novel

regimen (MODERN) , 396–397

Massachusetts General Hospital , 472, 623–624

MassARRAY system , 62–63

Mass spectrometry (MS) , 74–75, 241, 413

Matrix-assisted laser desorption ionization

mass spectrometry (MALDI-MS) ,

228, 261, 262, 350

Mayo Clinic , 268, 470, 620–621

Mayo Clinic Life Sciences System , 620

MDR. See Multidrug resistance (MDR)

Medical education , 629–630

Medulloblastomas , 290

Melacine melanoma , 244

Melanoma antigen gene-A3 (MAGE A3) , 241

MenaCalc™ Prostate , 362

Mena protein , 233, 234

Mendelian diseases , 8, 18, 539

Meningiomas , 291

Metabolomics , 19, 580

of Alzheimer’s disease , 419

biomarkers

advantages , 172

data processing and validation , 174

FT-ICR , 172

GC-TOF-MS applications , 172

identifi cation and pattern recognition ,

173–174

Index